Driving clarity in clinical development
Powered by digital twins, data, and AI
Every clinical trial is a chain of high-stakes decisions made by experts working across fragmented data, tools, and institutional memory. Unlearn integrates the evidence, modeling, and reasoning behind those decisions, so trial teams can commit with confidence, and so each decision builds on the last.
Real-world Results
Control Arm Size Reduction*
33%
Enrollment Time Saved (months)*
4+
*Approximate values
Accelerating Clinical Development in Alzheimer’s Disease
We work in neuroscience, immunology, metabolic disease, and more.
Solutions
The scientific intelligence layer for clinical development
Every trial is a chain of key decisions. We help you make each one more confidently.
Plan, monitor, analyze — one connected platform organized around the key decisions that shape every clinical trial.
Plan
Trial Planning and Simulations
One workspace for upstream trial design
Unlearn brings together the critical components required for trial design — where decisions are iterative, assumptions evolve, and rationale must remain clear and defensible across review cycles.
Scout
Continuously search, structure, and summarize relevant literature and regulatory precedent from sources like PubMed, ClinicalTrials.gov, and drugs@FDA — all in one place. Eliminate scattered searches and align on precedent in days, not weeks.
Hindsight
Explore harmonized clinical trial and real-world datasets to validate clinical and statistical assumptions. Assess population characteristics, endpoint behavior, and benchmarks.
SimLab
Build and compare trial-design scenarios to evaluate endpoints, inclusion/exclusion criteria, sample size, and constraints. Every scenario is reproducible, and linked to underlying evidence — supporting informed design trade-offs before protocol finalization.
Monitor
Anomaly Detection & Clinical Data Surveillance
Continuous patient and site-level monitoring of clinical data.
Detect anomalies as they emerge — unexpected values, off-trajectory responders, and multi-variate signals benchmarked against historical patient trajectories rather than generic, population-wide cutoffs.
Analyze
Trial Analyses with Digital Twins
Strengthen trial analyses with digital twins—AI-generated forecasts of clinical trial participants’ expected control outcomes.
Used as external comparators in early-stage and open-label studies, digital twins reduce variability and improve the ability to detect treatment effects. The same approach extends to randomized trials, where digital twins can support smaller sample sizes or increased power.
This methodology is qualified by the EMA and aligned with current FDA guidance, enabling clearer go/no-go decisions earlier in development and more efficient late-stage trials, with measurable reductions in trial size, cost, and time to readout.
Trusted by leading sponsors
“The ecosystem at the moment doesn’t sustain the way we’ve been doing it traditionally. And (Unlearn) is at the leading edge of this thinking.”
Kasper Roet, founder and CEO of QurAlis
View Presentation
"The collaboration with Unlearn and the resulting data further increases our confidence in our pioneering approach towards achieving symptomatic relief and disease modification in Alzheimer’s. This will support our efforts to advance an optimized second-generation therapy. Digital twins offer a new lens for interpreting biomarker trends over time—especially in early-stage trials where every data point matters."
Gerard Griffioen, Ph.D., CSO of remynd
See Press Release
"Working with Unlearn to mine their extensive, well-curated database through the use of the ALS DTG will enable us to explore smarter designs and make confident and informed decisions as we plan our Phase 1/2 trial. Ultimately, these insights can help us to move faster for people living with ALS who are waiting for new treatment options."
Eric Green, M.D., Ph.D., co-founder and CEO of Trace Neuroscience
See Press Release
Partnerships
Collaborating with leaders to move the industry forward.
Explore how leading biopharma companies are applying Unlearn’s AI-powered solutions in active studies today to reach clinical milestones faster.